Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 13.28 USD -1.99% Market Closed
Market Cap: 217m USD
Have any thoughts about
Biostem Technologies Inc?
Write Note

Operating Margin
Biostem Technologies Inc

9.8%
Current
-55%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9.8%
=
Operating Profit
20.5m
/
Revenue
210.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Biostem Technologies Inc
OTC:BSEM
217m USD
10%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.5B USD
22%
Country US
Market Cap 217m USD
Operating Margin
10%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Biostem Technologies Inc
Glance View

Market Cap
217m USD
Industry
Pharmaceuticals

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.

BSEM Intrinsic Value
18.02 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
9.8%
=
Operating Profit
20.5m
/
Revenue
210.4m
What is the Operating Margin of Biostem Technologies Inc?

Based on Biostem Technologies Inc's most recent financial statements, the company has Operating Margin of 9.8%.